Prognostic value and biological role of the kallikrein-related peptidases in human malignancies.
Cancer is a substantial health problem for the populations of the Western world. The discovery of new molecular biomarkers for diagnosis, prognosis and monitoring patients' response to therapy can aid in combating this complicated disease. The human kallikrein-related peptidases (human tissue kallikreins [KLKs]) are encoded by a continuous multigene family, located on chromosomal region 19q13.3-4. KLK3 (prostate-specific antigen) is the most efficient cancer biomarker ever employed. KLK genes are expressed abnormally in various malignancies, where they affect cancer-cell growth and metastasis. Their deregulated expression pattern, often associated with various clinicopathological characteristics of cancer patients, can be exploited, solely or within multiparametric panels, as a prognostic biomarker. Recent data illustrate that discernible molecular modulations of KLKs, occurring as a result of cancer cells' treatment with antitumor agents, may serve as new potential biomarkers, possibly predicting patients' treatment response. It is believed that KLKs might be employed in future clinical practice as novel and effective tumor markers.
Department of Biochemistry & Molecular Biology, University of Athens, Athens, Greece. mavridiskos@gmail.com
Konstantinos
K
Mavridis
Andreas
A
Scorilas
D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D009369:Neoplasms / Q000201:enzymology* / Q000235:genetics; D011379:Prognosis; D020840:Tissue Kallikreins / Q000235:genetics / Q000378:metabolism*
D014408:Biomarkers, Tumor; D020840:Tissue Kallikreins